Leveraging Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies
Selecta gains rights to develop and commercialize select therapeutic enzymes from Ginkgo's advanced organism engineering platform to treat select auto-immune diseases
https://finance.yahoo.com/news/selecta-biosciences-ginkgo-bioworks-announce-120000741.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.